Status:
COMPLETED
PET/CT and Bacterial/Fungal PCR in High Risk Febrile Neutropenia
Lead Sponsor:
Peter MacCallum Cancer Centre, Australia
Collaborating Sponsors:
Melbourne Health
Westmead Hospital
Conditions:
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Patients with acute leukaemia requiring induction or consolidation chemotherapy and those requiring a haematopoietic stem cell transplant are at high risk of fever and infection when they have low whi...
Eligibility Criteria
Inclusion
- About to have an allogeneic haematopoietic stem cell transplant, OR
- About to have an autologous haematopoietic stem cell transplant, OR
- Commencing induction or consolidation chemotherapy with curative intent for acute myeloid or acute lymphoid leukaemia
Exclusion
- Current actively diagnosed infection prior to transplant or chemotherapy
- Allergy to intravenous contrast for CT imaging
- eGFR \<30
- Pregnant
Key Trial Info
Start Date :
January 8 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 23 2021
Estimated Enrollment :
147 Patients enrolled
Trial Details
Trial ID
NCT03429387
Start Date
January 8 2018
End Date
January 23 2021
Last Update
May 17 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia, 3000
2
Melbourne Health
Parkville, Victoria, Australia, 3052